Mylan Ruling Will 'Drastically' Alter Hatch-Waxman Litigation
Appeals Court Ruling In US Limits Venue For Paragraph IV Filings
An appeals court ruling in the US stands to “drastically change” the venue options for brand companies to sue ANDA filers.
You may also be interested in...
Mylan disputed Valeant's complaint in New Jersey federal court for improper venue, on the basis that Valeant firm had no relevant ties to New Jersey and the only alleged act of infringement – submission of the ANDA – did not occur there.
A ruling that could play a key role in limiting venue for Hatch-Waxman litigation in the US will not be reviewed by the full US Court of Appeals for the Federal Circuit after it refused a rehearing petition by Valeant.
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.